Company / Accounts Receivable
IRADIMED CORP Accounts Receivable History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$13.7M
FY2025
5-year range
$5.1M / $13.7M
FY2021-FY2025
Trend
+29.5%
vs FY2024
Sector context
#133 of 138
Health Care
What the data says
Among 138 Health Care companies, IRADIMED CORP is in the bottom 4% for accounts receivable. Accounts Receivable returned to growth in FY2025 after 2 years of decline, reaching $14M.
Based on SEC 10-K filings.
$14M in FY2025 with a 5-year CAGR of +24.5%.
Improved from $12M to $14M over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +1.0%
- 5-Year CAGR
- +24.5%
- 10-Year CAGR
- -
Sector benchmark
Bottom 4% in Health CareTop 96% of 138This company $13.7M Sector average $1.3B
▼
-99.0% below sector average
Key checks
Key Insights
- 5-year CAGR of +24.5%, indicating consistent growth.
- In FY2025, accounts receivable increased 29.5% year-over-year.
- Ranks #133 out of 138 companies in the Health Care sector.
- Lowest accounts receivable in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score 5.29 (safe zone, above 2.9 threshold)
- Strong profit margin: 24.1%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $13.7M | +29.5% |
| FY2024 | $10.6M | -13.6% |
| FY2023 | $12.2M | -7.9% |
| FY2022 | $13.3M | +158.4% |
| FY2021 | $5.1M | +12.3% |
| FY2020 | $4.6M | -37.3% |
| FY2019 | $7.3M | +73.2% |
| FY2018 | $4.2M | +11.4% |
| FY2017 | $3.8M | +0.1% |
| FY2016 | $3.8M | -2.3% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026